Faculty Profile: Katharine Phillips, MD

Katharine Phillips, MD
Professor of Psychiatry & Human Behavior
Psychiatry & Human Behavior
Work: +1 401-444-1646
Dr. Phillips has done pioneering research on body dysmorphic disorder (BDD), a common and severe disorder. Current research studies include the development and investigation of treatments for BDD, examination of visual processing in BDD, and clinical features of olfactory reference syndrome. Dr. Phillips has published more than 275 scientific articles, review articles, and book chapters. To disseminate her research findings on BDD, she has written books and lectures extensively in the US and abroad.

Biography

Katharine A. Phillips, M.D., is Professor of Psychiatry and Human Behavior and Director of Research Training for the General Psychiatry Residency Training Program at the Alpert Medical School of Brown University. She is also Senior Research Scientist, Director of Research for Adult Psychiatry, and Director of the Body Dysmorphic Disorder Program at Rhode Island Hospital.

Dr. Phillips is an internationally recognized researcher and expert on body dysmorphic disorder (BDD). She has also conducted research on obsessive compulsive disorder, olfactory reference syndrome, and other psychiatric disorders. Dr. Phillips' research on BDD has been continuously funded by the National Institute of Mental Health since 1995. She has received numerous honors and awards for her research, clinical work, and other academic contributions, including a Special Presidential Commendation from the American Psychiatric Association for her research accomplishments.

Dr. Phillips has published more than 275 original scientific articles, review articles, and book chapters. She has also published five first-authored or co-authored books and three edited books on BDD and other topics. She has done more than 450 international, national, and local presentations for professionals (including more than 110 Grand Rounds) and hundreds of media interviews.

Dr. Phillips is an elected Fellow of the American College of Neuropsychopharmacology, and she is a member of numerous editorial boards, the American College of Psychiatrists, and the Scientific Advisory Boards of the Anxiety Disorders Association of America and the International OCD Foundation. From 2002-2006 she chaired the National Institute of Mental Health's Interventions Research Review Committee (Scientific Review Group). Dr. Phillips has been included in Marquis Who's Who in Science and Engineering, Who's Who in Medicine and Healthcare, and Who's Who of American Women. She has also repeatedly been included in Who's Who in America, Best Doctors in America, and Castle Connolly's America's Top Doctors.

Institutions

Bh

Research Description

For more than 20 years, my research has focused primarily on body dysmorphic disorder (BDD), a common and severe disorder that is associated with markedly poor psychosocial functioning and high rates of suicidality. I have also conducted research on obsessive-compulsive disorder, olfactory reference syndrome, and other psychiatric disorders. When I started my research on BDD, virtually no systematic research had been done on this disorder. My BDD research has focused primarily on the development and testing of treatments for BDD, both psychosocial and pharmacologic. The other major focus of my work has been psychopathology research, including suicidality, insight, comorbidity, impairment in psychosocial functioning, and BDD's relationship to other disorders. I have also studied BDD's prevalence and course of illness, have developed widely used BDD and insight measures, and have collaborated on neuroimaging, molecular genetics, and neuropsychological studies of BDD. More than 180 of my publications focus primarily on BDD.

Currently funded studies are examining treatment of BDD with cognitive-behavioral therapy vs supportive psychotherapy, investigation of visual processing in BDD, and features of olfactory reference syndrome.

Grants and Awards

Summa Cum Laude, Phi Beta Kappa, and Rufus Choate Scholar; Dartmouth College

Alpha Omega Alpha, Rolf Syvertsen Fellow for outstanding academic performance, and the Dean's Medal; Dartmouth Medical School

Outstanding Resident Award, National Institute of Mental Health

American Psychiatric Association/Burroughs-Wellcome Fellow, American Psychiatric Association

Resident Research Award, American Psychiatric Association

Psychiatric Research Fellowship Honorable Mention, American Psychiatric Association

Paul Howard Award, McLean Hospital

Young Investigator Award, National Alliance for Research on Schizophrenia and Depression

New Investigator Travel Award Recipient; New Clinical Drug Evaluation Unit; National Institute of Mental Health

Outstanding Psychiatrist Award for Clinical Psychiatry, Massachusetts Psychiatric Society

Travel Award, American College of Neuropsychopharmacology

Honorable Mention, Gerald Klerman Award; National Alliance for Research on Schizophrenia and Depression

Literary Award (for The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder), Rhode Island Medical Women's Association

Master of Arts ad eundem (honorary degree), Brown University

Best Doctors in America (National Edition) (2001-2003, 2005-2006, 2007-2008, 2009-2010, 2011-2014)

Department of Psychiatry and Human Behavior Research Mentor Award, The Warren Alpert Medical School of Brown University, 2001, 2007

2002 Dorfman Journal Paper Award, Academy of Psychosomatic Medicine

Distinguished Fellow, American Psychiatric Association

Special Presidential Commendation (for research on body dysmorphic disorder), American Psychiatric Association

America's Top Doctors, 2007 - 2013, Castle Connolly Medical Ltd.

Fellow, American College of Neuropsychopharmacology

US News and World Report Best Doctors, 2011-2013

Affiliations

American Psychiatric Association, 1986-present (currently a Distinguished Fellow)

American Medical Association, 1986-present

International Society for the Study of Personality Disorders, 1991-present

Association for Research on Personality Disorders, 1992-present

Rhode Island Psychiatric Society, 1994-present

Rhode Island Medical Society, 1995-present

International Obsessive-Compulsive Disorder Foundation, 1998-present (currently Member of Scientific Advisory Board)

American Psychopathological Association, 1999-present (Member)

American College of Neuropsychopharmacology, 2004-present (currently a Fellow)

Association of Women Psychiatrists, 2005-present

American College of Psychiatrists, 2007-present

Anxiety Disorders Association of America, 2008-present (currently Member of Scientific Council)

Funded Research

Livingston Research Fellowship
Harvard Medical School
Principal Investigator, 1991-1992

Development of Diagnostic Instruments and Prevalence of Body
Dysmorphic Disorder in Psychiatric, Medical, and Surgical Populations
Young Investigator Award, National Alliance for Research on Schizophrenia and Depression (NARSAD)
Principal Investigator, 1992-1996

An Open-Label Flexible Dose Study of Fluvoxamine in Body Dysmorphic Disorder
Upjohn/Solvay Pharmaceuticals (Investigator Initiated)
Co-Principal Investigator, 1994-1995

A Prospective, Multicenter, Open-Label Study of Serzone (Nefazodone) in the Management of Patients with Symptoms of Depression in General Psychiatric Practices
Bristol-Myers Squibb Company
Co-Investigator, 1995

The Pharmacotherapy of Body Dysmorphic Disorder
National Institute of Mental Health (R29-MH54841 [FIRST Award])
Principal Investigator, 1995-2000

Pimozide Augmentation of Fluoxetine in Body Dysmorphic Disorder
Young Investigator Award, National Alliance for Research on Schizophrenia and Depression (NARSAD)
Principal Investigator, 1995-2002

Retrospective Follow-up Study of Body Dysmorphic Disorder
Department of Psychiatry, Brown Medical School
Principal Investigator, 1996-1998

Fluoxetine in the Continuation Treatment of Major Depressive Disorder
Eli Lilly and Company
Co-Investigator, 1997-1998

Phenomenology of Body Dysmorphic Disorder in Children and Adolescents
Solvay Pharmaceuticals (Investigator Initiated)
Co-Principal Investigator, 1997-2000

Harvard/Brown Anxiety Research Program
National Institute of Mental Health (5 R01 MH51415)
Co-Investigator, 1998-2008

Citalopram Treatment of Body Dysmorphic Disorder
Forest Laboratories (Investigator Initiated)
Principal Investigator, 1999-2001

Pharmacotherapy of Adolescent Body Dysmorphic Disorder
National Institute of Mental Health (1 R01 MH58750)
Principal Investigator, 1999-2003

Pilot Study of the Genetics of Body Dysmorphic Disorder
Department of Psychiatry, Brown Medical School
Principal Investigator, 1999-2003

Olanzapine Augmentation of Fluoxetine in Body Dysmorphic Disorder
Eli Lilly and Company (Investigator Initiated)
Principal Investigator, 1999-2003

Visual Processing in Body Dysmorphic Disorder
Department of Psychiatry, Brown Medical School
Principal Investigator, 2000-2001

Prospective Study of Body Dysmorphic Disorder
National Institute of Mental Health (R01 MH60241)
Principal Investigator, 2000-2006

Treatment and Psychopathology of Body Dysmorphic Disorder
National Institute of Mental Health: Mid-Career Investigator Award in Patient-Oriented Research (5K24 MH063975)
Principal Investigator, 2001-2013

Escitalopram Treatment of Body Dysmorphic Disorder
Forest Laboratories (Investigator Initiated)
Principal Investigator, 2003-2005

CBT Treatment Development in Body Dysmorphic Disorder
National Institute of Mental Health (R34 MH070490)
Co-Principal Investigator, 2004-2009

Open-Label Study of Levetiracetam in Body Dysmorphic Disorder
UCB Pharma (Investigator Initiated)
Principal Investigator, 2004-2008

Fluoxetine in Pediatric Body Dysmorphic Disorder
Food and Drug Administration (FD-R-002613)
Co-Principal Investigator, 2005-2012

Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder
National Institute of Mental Health (R01 MH072917)
Principal Investigator, 2005-2011

A Prospective Study of Suicidal Ideation, Suicide Attempts, and Completed Suicide in Body Dysmorphic Disorder
American Foundation for Suicide Prevention
Principal Investigator, 2007-2010

Safety of Low-Dose Ondansetron for Adjunctive Therapy in Adult Patients with Obsessive Compulsive Disorder Who Have Not Adequately Responded to Treatment with a Selective Serotonin Reuptake Inhibitor
Transcept Pharmaceuticals
Co-Investigator, 2011-2012

Cognitive-Behavioral Therapy Versus Supportive Psychotherapy for Body Dysmorphic Disorder
National Institute of Mental Health (R01 MH091023)
Principal Investigator, 2011-2016

Visual Processing in Body Dysmorphic Disorder
Brown Institute for Brain Science and Norman Prince Neurosciences Institute
Principal Investigator (with David Sheinberg, Ph.D.), 2013-2014

Promoting Research Training During Psychiatry Residency
National Institute of Mental Health (1R25 MH101076)
Principal Investigator, 2013-2018

Teaching Experience

Dr. Phillips is Director of Research Training for the General Psychiatry Residency Training Program at the Alpert Medical School of Brown University. She is also Principal Investigator on an R-25 grant from the National Institute of Mental Health, which provides research training for psychiatry residents at Brown University. In addition, she is Co-Director of a Post-Doctoral Research Training Fellowship that is sponsored by the Brown Institute for Brain Science, the Norman Prince Neuroscience Institute, and Brown University's Department of Psychiatry and Human Behavior (with Justin Fallon, Ph.D.). Dr. Phillips also provides research mentoring to beginning and early-career researchers (for example, junior faculty, research fellows, undergraduate students). For more than a decade, she was Principal Investigator on a K24 grant from the National Institute of Mental Health, which involved research mentoring. Dr. Phillips additionally provides research teaching and mentoring at national events, such as the annual meetings of the American College of Neuropsychopharmacology, the American Psychiatric Association, and the American Society for Clinical Psychopharmacology.

Selected Publications

  • Phillips KA, Menard W, Quinn E, Didie ER, Stout RL. A four-year prospective observational follow-up study of course and predictors of course in body dysmorphic disorder. Psychological Medicine 2013;43:1109-1117 (2013)
  • Wilhelm S, Phillips KA, Steketee G. Cognitive-Behavioral Therapy for Body Dysmorphic Disorder: A Treatment Manual. New York: Guilford Press, 2013 (2013)
  • Phillips KA, Pinto A, Hart AS, Coles ME, Eisen JL, Menard W, Rasmussen SA. A comparison of insight in body dysmorphic disorder and obsessive-compulsive disorder. Journal of Psychiatric Research 2012;46:1293-1299 (2012)
  • Phillips KA, Menard W. Olfactory reference syndrome: demographic and clinical features of imagined body odor. General Hospital Psychiatry 2011;33:398-406 (2011)
  • Phillips KA, Wilhelm S, Koran LM, Didie ER, Fallon BA, Feusner J, Stein DJ. Body dysmorphic disorder: Some key issues for DSM-V. Depression and Anxiety 2010;27:573-591 (2010)
  • Phillips KA, Stein DJ, Rauch SL, Hollander E, Fallon BA, Barsky A, Fineberg N, Mataix-Cols D, Ferrão YA, Saxena S, Wilhelm S, Kelly MM, Clark LA, Pinto A, Bienvenu OJ, Farrow J, Leckman J. Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V? Depression and Anxiety 2010;27:528-555 (2010)
  • Phillips KA. Body dysmorphic disorder. In: New Oxford Textbook of Psychiatry, Second Edition. Gelder M, Andreasen N, Lopez-Ibor J, Geddes J, eds. Oxford, England: Oxford University Press, 2009 (2009)
  • Phillips KA, Kelly MM. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder. International Clinical Psychopharmacology 2009;24:26-28 (2009)
  • Phillips KA. Understanding Body Dysmorphic Disorder: An Essential Guide. New York: Oxford University Press, 2009 (2009)
  • Phillips KA, Didie ER, Feusner J, Wilhelm S. Body dysmorphic disorder: treating an underrecognized disorder. American Journal of Psychiatry 2008;165:1111-1118 (2008)
  • Phillips KA, Quinn G, Stout RL. Functional impairment in body dysmorphic disorder: a prospective, follow-up study. Journal of Psychiatric Research 2008;42:701-707 (2008)
  • Phillips KA, Pagano ME, Menard W, Stout RL. A 12-month follow-up study of the course of body dysmorphic disorder. American Journal of Psychiatry 2006;163:907-912 (2006)
  • Phillips KA, Menard W, Fay C. Gender similarities and differences in 200 individuals with body dysmorphic disorder. Comprehensive Psychiatry 2006;47:77-87 (2006)
  • Phillips KA, Menard W. Suicidality in body dysmorphic disorder: a prospective study. American Journal of Psychiatry 2006;163:1280-1282 (2006)
  • Phillips KA. The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. Revised and Expanded Edition. New York: Oxford University Press, 2005 (2005)
  • Phillips KA, Coles M, Menard W, Yen S, Fay C, Weisberg RB. Suicidal ideation and suicide attempts in body dysmorphic disorder. Journal of Clinical Psychiatry 2005;66:717-725 (2005)
  • Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Archives of General Psychiatry 2002;59:381-388 (2002)
  • Pope HG Jr, Phillips KA, Olivardia R. The Adonis Complex: The Secret Crisis of Male Body Obsession. New York: The Free Press, 2000 (Paperback edition: The Adonis Complex: How to Identify, Treat, and Prevent Body Obsession in Men and Boys. New York: The Free Press, 2002) (2000)
  • Phillips KA, McElroy SL, Keck PE Jr, Pope HG Jr, Hudson JI. Body dysmorphic disorder: 30 cases of imagined ugliness. American Journal of Psychiatry 1993;150:302-308 (1993)